HIGHLIGHTS
- who: Joanna Obacz from the Cambridge InstituteUniversity of London, London, UK have published the article: Biological basis for novel mesothelioma therapies, in the Journal: (JOURNAL) of 14/01/2021
- what: The authors provide a comprehensive summary of previous and current clinical trials. In this approach, homologous T_cells are collected from the individual, genetically engineered to express a tumour-specific antigen receptor and, following ex vivo expansion, re-administered to the patient.
- how: This result was supported by data from a phase Ib study of 34 patients treated with GSK2256098 plus the MEK inhibitor . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.